Maysa Abu Khalaf, MD

Maysa Abu Khalaf, MD

Contact Dr. Abu Khalaf

1025 Walnut Street
Suite 700
Philadelphia, PA 19107

(215) 503-5088
(215) 503-3408 fax

Most Recent Peer-reviewed Publications

  1. Chemotherapy Agents With Known Cardiovascular Side Effects and Their Anesthetic Implications
  2. Impacts of early guideline-directed 21-gene recurrence score testing on adjuvant therapy decision making
  3. Racial and ethnic disparities in oncotype DX test receipt in a statewide population-based study
  4. A Case of Carcinocythemia: De Novo Hormone Receptor-positive Metastatic Breast Cancer Presenting With Circulating Tumor Cells Mimicking an Acute Leukemia
  5. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer
  6. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition
  7. Immune signatures following single dose trastuzumab predict pathologic response to preoperativetrastuzumab and chemotherapy in HER2-positive early breast cancer
  8. Patient preferences regarding incidental genomic findings discovered during tumor profiling
  9. New strategies in breast cancer: Immunotherapy
  10. Mutation based treatment recommendations from next generation sequencing data: A comparison of web tools
  11. Influence of a 21-Gene Recurrence Score Assay on Chemotherapy Delivery in Breast Cancer
  12. Association of 21-gene recurrence score assay and adjuvant chemotherapy use in the medicare population, 2008-2011
  13. Relationship between complete pathologic response to neoadjuvant chemotherapy and survival in triple-negative breast cancer
  14. Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma
  15. Brief-exposure to preoperative bevacizumab reveals a TGF-β signature predictive of response in HER2-negative breast cancers
  16. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer
  17. Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy
  18. Use of neoadjuvant chemotherapy for patients with stage i to III breast cancer in the United States
  19. Systematic approach to providing breast cancer survivors with survivorship care plans: A feasibility study
  20. Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors